Company intelligence / Profile preview

Acerand Therapeutics

Shanghai, Shanghai, Chinacenterwatch.com ↗

Ownership: Private
Development stage: Other

Overview

Acerand's lead compound ACE-232 (CYP11A1 inhibitor) received FDA approval for Phase 1 clinical trials in January 2025 for prostate cancer. Their PARP1 inhibitor ACE-86225106 has entered Phase 1/2 trials. Preclinical data for ACE-232 shows superior potency compared to competitor compound ODM-208 (MK-5684).

Therapeutic areas: OncologyImmunologyPulmonology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

7 assets

ACE-86225106

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Acerand Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acerand Therapeutics.

Explore the full profile